Targeted-therapy in advanced renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Surgery, including nephrectomy, is standard for resectable renal cell carcinoma (RCC).
• Metastatic RCC requires new therapies due to limited immunotherapy response rates.
• VHL gene mutations in clear cell RCC lead to VEGF overexpression, a key therapeutic target.

Purpose of the Study:

• To review recent advances in molecular targeted therapy for metastatic RCC.
• To focus on the chemical structure and mechanism of action of VEGFR and mTOR inhibitors.

Main Methods:

• Literature review of molecular targeted therapies for metastatic RCC.
• Analysis of VEGFR and mTOR inhibitors' chemical structures and mechanisms.

Main Results:

• Bevacizumab validated VEGF as a target in clear cell RCC.
• Sunitinib and sorafenib are key therapies targeting VEGF pathway.
• mTOR inhibitors like temsirolimus and everolimus show survival and progression-free survival benefits.

Conclusions:

• Molecular targeted therapies, particularly VEGFR and mTOR inhibitors, offer new hope for metastatic RCC.
• Understanding drug mechanisms is vital for optimizing treatment strategies.